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Abstract
Background: Pancreatic cancer is the fourth most common cause of cancer related death in
Western countries. Advantages in surgical techniques, radiation and chemotherapy had almost no
impact on the long term survival of affected patients. Therefore, the need for better treatment
strategies is urgent. HER2, a receptor tyrosine kinase of the EGFR family, involved in signal
transduction pathways leading to cell growth and differentiation is overexpressed in a number of
cancers, including breast and pancreatic cancer. While in breast cancer HER2 has already been
successfully used as a treatment target, there are only limited data evaluating the effects of inhibiting
HER2 tyrosine kinases in patients with pancreatic cancer.
Methods: Here we report the design of a prospective, non-randomized multi-centered Phase II
clinical study evaluating the effects of the Fluoropyrimidine-carbamate Capecitabine (Xeloda ®) and
the monoclonal anti-HER2 antibody Trastuzumab (Herceptin®) in patients with non-resectable,
HER2 overexpressing pancreatic cancer. Patients eligible for the study will receive Trastuzumab
infusions on day 1, 8 and 15 concomitant to the oral intake of Capecitabine from day 1 to day 14
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of each three week cylce. Cycles will be repeated until tumor progression. A total of 37 patients
will be enrolled with an interim analysis after 23 patients.
Discussion: Primary end point of the study is to determine the progression free survival after 12
weeks of bimodal treatment with the chemotherapeutic agent Capecitabine and the anti-HER2
antibody Trastuzumab. Secondary end points include patient's survival, toxicity analysis, quality of
life, the correlation of HER2 overexpression and clinical response to Trastuzumab treatment and,
finally, the correlation of CA19-9 plasma levels and progression free intervals.
Background
Pancreatic cancer it is the fourth most common cause of
cancer related death in Western countries [1]. A recent
database study revealed that surgical therapy is the most
important predictor of long-term survival but only 10.4%
of patients were resectable [2]. Median survival after resec-
tion was 13 months among compared to a median sur-
vival of 4 months in patients not amendable to surgery
[2]. Since most patients develop tumor recurrence the
mainstay of treatment is gemcitabine based chemother-
apy [3,4]. Gemcitabine-based combination therapies did
not lead to further improvements in survival, although
the combination of gemcitabine with capecitabine has
shown promising results [4]. A potentially promising
combination therapy is capecitabine (Xeloda™) which can
be orally administered and the molecular target com-
pound Trastuzumab (Herceptin™), which is a neutralizing
humanized antibody directed against the extracellular
domain of the HER2 tyrosine receptor kinase.
Capecitabine is an orally applied fluoropyrimidine, which
is converted into active 5-FU. Within this enzymatic cas-
cade thymidinephosphorylase finally catalyzes the gener-
ation of active 5-Fluoruracil (5-FU).
Thymidinephosphorylase is almost exclusively present in
tumor cells, the activation of capecitabine to 5-FU is
restricted to malignant cells. When applied twice daily
capecitabine shows similar pharmacokinetics as a contin-
uous 5-FU infusion [5]. Based on several clinical trials the
toxicity of capecitabine appears low [6,7]. Common side
effects include abdominal symptoms like diarrhea, nau-
sea, vomiting as well as dermatologic symptoms like der-
matitis or the hand-foot syndrome. Noteworthy,
capecitabine has been reported to be cardiotoxic inducing
myocardiac infarction, angina and arrhythmias [8].
Recent phase III trials comparing gemcitabine mono-
therapy to a combination of gemcitabine plus capecitab-
ine did not result in a significant survival benefit [9-11].
Trastuzumab is a neutralizing humanized antibody
directed against the extracellular domain of the HER2
tyrosine receptor kinase. Expression of the HER2neu
oncogen is analyzed by immunohistochemistry (IHC)
and fluorescent in-situ hybridization (FISH) in routine
pathological specimen assessment. The antineoplastic
effect of Trastuzumab is well documented in breast cancer
and has been ascribed to cell cycle arrest and incuction of
apoptosis as well as induction of antibody-dependent cel-
lular cytotoxicity (ADCC) against HER2 – overexpressing
tumor cells [12]. A number of promising pre-clinical stud-
ies in pancreatic cancer suggest a potential therapeutic
benefit for those patients overexpressing HER2/neu [13-
15]. The rationale for applying trastuzumab in patients
with advanced pancreatic cancer is based on studies in
which 11% of human specimens overexpressed HER2
with a score of 3 and 26% with a score of 2 [16,17]. In a
recent phase II study in 21 patients with metastasized
HER2 overexpressing (grade 2–3) pancreatic cancer a
combination of trastuzumab and capecitabine resulted in
partial remission rates of 24% and 50% of patients
showed a reduction of the tumor marker CA19-9 [17].
Taken together, the need for novel therapeutic strategies
such as target therapy in pancreatic cancer patients is obvi-
ous. One approach involves targeting the HER2/neu
receptor in combination with cytotoxic agents. Based on
the poor outcome of current therapies, we evaluate the
activity and tolerability of the combination therapy of
trastuzumab plus oral capcitabine in patients with proven
HER2 overexpressing advanced pancreatic cancer.
Methods
Trial organization
This multicentric, multiinstitutional trial has been
designed by the Centre of Clinical Trials, University Med-
ical Center Freiburg and by LabConsult GmbH Freiburg.
The trial medication (trastuzumab and capecitabine) is
supplied by the Roche AG, Basel, Switzerland. Participat-
ing study centers are as follows:
￿ Department of General Surgery, University of Heidel-
berg, Im Neuenheimer Feld 110, 69120 Heidelberg, Ger-
many
￿ Department of Gastroenterology and Hepatology,
Freiburg University Hospital, Hugstetterstr. 55, 79106
Freiburg, GermanyBMC Surgery 2009, 9:1 http://www.biomedcentral.com/1471-2482/9/1
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￿ Department of Internal Medicine I, University Clinic
Tubingen, Ottfried-Müller-Str. 10, 72076 Tübingen, Ger-
many.
￿ Department of Internal Medicine I, Johannes Gutenberg
University, Langenbeckstr. 1, 55101 Mainz, Germany
￿ III. Medical Clinic, University Hospital Mannheim, Uni-
versity of Heidelberg, Wiesbadener Strasse 7–11, 68167
Mannheim, Germany
￿ Department of Medicine, Ruhr University Bochum
(Knappschaftskrankenhaus), In der Schornau 23–25,
44892 Bochum, Germany
￿ University of Munich, Medical Department III, Klini-
kum Muenchen-Grosshadern, Marchioninistrasse 15,
81377 Munich, Germany
￿ Department of Internal Medicine I, University of
Regensburg, Franz-Josef-Strauß-Allee, 93042 Regensburg,
Germany
￿ Department of Pathology, University of Kiel,
Michaelisstr.11, 24105 Kiel, Germany.
￿ Department of Medicine, Gastroenterology and Oncol-
ogy, Municipal Hospital Esslingen, Germany
Coordination
The trial is co-ordinated by the Centre of Clinical Trials,
University Medical Center Freiburg and by LabConsult
GmbH Freiburg. This institution is responsible for overall
trial management, trial registration, database manage-
ment, quality assurance including monitoring, reporting
and for the scientific program of all trial related meetings.
Investigators
Patients will be recruited by all participating institutions.
All investigators are experienced oncologists from the
fields of medical oncology and general surgery at co-oper-
ating institutes.
Adverse events management
For all severe serious adverse events the documentation
and relevant patient data are verified by the co-ordinating
personnel before submitting the data to the Center for
Clinical Trials, Freiburg as well as to Roche (Roche
Pharma AG, Grenzach-Wyhlen, Germany) with 24 h. The
German authorities will be informed by Roche in the case
of causal relationship. Severe adverse events are events
that cause:
￿ death of study subject
￿ life threatening illness
￿ hospitalization or
￿ extend of hospitalization
￿ permanent or significant discomfort/disabilities
Patient toxicities will be assessed using the NCI Common
Toxicity Criteria (CTC) 3.0 (June 2003). Toxicity will be
evaluated before treatment, and prior to each course of
trastuzumab and capecitabine and at follow-up. Unac-
ceptable toxicity is defined as unpredictable, or irreversi-
ble Grade 4 toxicity.
Medication supply
All chemotherapeutic agents are provided by the Roche
(Roche Pharma AG, Grenzach-Wyhlen, Germany) upon
request. Each request comprises 2 cycles (6 weeks).
Quality control
Quality control is achieved by monitoring, auditing and
data verification according to the good clinical practice
guidelines (GCP). To ensure correct documentation a spe-
cially trained independent trial monitor will perform reg-
ular visits in the study centers as well as checks on the
individual principal investigators. Source data verification
is done by the monitor to ensure that all data present in
the case report form corresponds to data in the original
documents present in the patient folder. Finally audits
will be held either by the sponsor or responsible authori-
ties.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Freiburg and by the local ethic com-
mittees of participating institutions. This study complies
with the Helsinki Declaration in its recent German ver-
sion, the Medical Association's professional code of con-
duct, the principles of Good Clinical Practice (GCP)
guidelines and the Federal Data Protection Act. The trial
will also be carried out in keeping with local legal and reg-
ulatory requirements. The medical secrecy and the Federal
Data Protection Act will be followed. Written informed
consent is obtained from each patient in oral and written
form before inclusion and after nature, scope, and possi-
ble consequences of the trial have been explained by a
physician. The investigator will not undertake any meas-
ures specifically required only for the clinical trial until
valid consent has been obtained.
Patient selection
Patients over 18 years of age with advanced pancreatic
cancer (Stage IVb) without the chance of surgical tumor
removal are potential candidates for the study and will beBMC Surgery 2009, 9:1 http://www.biomedcentral.com/1471-2482/9/1
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screened for inclusion. Recruitment started during the first
trimester of 2004 and is expected to be completed within
a 36 months period. Table 1 outlines a detailed list of the
eligibility criteria of this study. An outline of the recruit-
ment algorithm is provided in Figure 1. A total of 37
patients will be included with an interim analysis held
after 23 patients.
Study design and objectives
The study is designed as a prospective, open, one-armed
multicentric Phase-II trial evaluating the efficacy of trastu-
zumab in combination with capecitabine compared to
capecitabine alone in patients with advanced pancreatic
cancer. Efficacy is evaluated by the primary study objective
which is progression free survival after 12 weeks. Second-
ary study objectives are to assess efficacy by evaluating: a)
progression free survival time; b) overall survival; c) time
till remission (partial or complete); d) duration of remis-
sion; e) rate of "clinical benefit response" after 12 weeks;
f) quality of life before treatment and after two 2 cycles of
chemotherapy. Additional secondary trial endpoints
include toxicity analysis, the rate of adverse events and the
relationship between progression free survival and CA19-
9 plasma levels. Finally, the relation between HER2/neu
overexpression and progression free survival will be eval-
uated.
Standardized treatment protocol
The trastuzumab loading dose of 4 mg/kg body weight
will be given on day 1 over 90 min. For maintenance ther-
apy a weekly dose of 2 mg/kg body weight over 30 min
will be infused until tumor progression takes place.
Patients will be monitored closely for 6 hours during the
first dose of trastuzumab and for 2 hours after the follow-
ing trastuzumab infusions to rule out adverse reactions.
Capecitabine will be applied orally twice daily at a dose of
1250 mg/m2 on day 1–14 followed by a break of 7 days.
The three weeks cycles will be repeated till tumor progres-
sion or till a grade 3–4 toxicity occurs. A detailed overview
over the treatment protocol is outlined in Table 2. In case
of adverse reactions of capecitabine therapy, a modifica-
tion of the dose will be performed (Table 3). There is no
dose modification in the case of trastuzumab. In the case
of a grade 3–4 toxicity trastuzumab therapy is stopped
until the toxicity is reduced to grade 2 or lower.
Table 1: List of the eligibility criteria
Inclusion criteria Exclusion criteria
1. written informed consent 1. possible surgical resection and/or radiotherapy with curative potential
2. age 18 years or older 2. dihydropyrimidine-dehydrogenase deficiency
3. histological verified pancreatic cancer in stage IVB (T1–4N0M1) 3. gastrointestinal obstruction
4. staging and CA19-9 serum level not older than 4 weeks 4. a known secondary neoplasm except a curative treatable basalioma of 
the skin or carcinoma in situ of the cervix uteri
5. histological verified over-expression of HER2/neu 
(immunological score 3+ or 2+ and HER2/neu gene amplification in FISH 
analysis)
5. a known hypersensitivity against any of the applied substances
6. at least one measurable lesion ( 2 cm in conventional CT scan or  1 
cm in spiral CT scans)
6. clinically relevant disorder of the cardio-vascular system or other 
organs or a severe systemic disease that compromises the study 
protocol or the interpretation of the data
7. no prior radiation or chemotherapy 7. clinically manifest pulmonary disorder
8. performance-status 0–2 according to WHO/ECOG or  60 points on 
the Karnofsky scale
8. prior polyneuropathy
9. life expectancy of at least 3 months 9. a concomitant treatment with the virusstatic agents Sorivudin or its 
analogues
10. Left ventricular excretion fraction > 50% 10. pregnancy, breast feeding or absence of appropriate contraceptive 
measures
11. appropriate renal, liver and hematopoetic function defined by: 11. psychiatric disorders, drug abuse or other disorders, that 
compromise the informed consent
a. neutrophils  1.5 × 109/l
b. hemoglobin  80 g/l
c. platelets  100 × 109/l
d. total bilirubin < 3 × normal
e. creatinine clearance  30 ml/min (Cockroft Gault)
f. transaminases
i. < 2.5 × normal
ii. < 5 × normal in case of liver metastases
12. possibility of long-term follow up 12. concomitant participation in other clinical trials or participation 
within the last 4 weeks
13. negative pregnancy testing 13. any other disorder or treatment that poses a risk to the patient or is 
incompatible with the aims of this studyBMC Surgery 2009, 9:1 http://www.biomedcentral.com/1471-2482/9/1
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Trial flow chart Figure 1
Trial flow chart. Flow chart summarizing the multi step process from initial patient contact until the inclusion of properly 
screened patient into the trial. Once diagnosis of pancreatic cancer stage IVb was established patients were screened for inclu-
sion criteria. If patients met all inclusion criteria and no exclusion criteria prohibited participation in the study an informed con-
sent was signed. All patients underwent histological confirmation and HER2 grading in the centralized reference pathology. 
Patients with HER2 grade 3 and patients with HER2 grade 2 plus proven HER2 gene amplification in FISH analyses were eligible 
for study inclusion. All other patients with HER2 grade 0, 1, or 2 without gene amplification were excluded from this study.
Screening
Histologically verified, non-
resectable carcinoma of the 
pancreas (Stadium IVb)
Evaluation of inclusion and 
exclusion criteria
Signed informed consent form
Primary Documentation
Independent of later 
inclusion/exclusion 
Performed by the study center





Fluorescence in situ Hybridization (FISH)
central specimen analysis at study reference pathology:
Department of Pathology, University of Kiel, Germany
HER2 Expression 
Grade 3+ (IHC)





Registration at coordinating study 
center (Freiburg)
Study exclusionBMC Surgery 2009, 9:1 http://www.biomedcentral.com/1471-2482/9/1
Page 6 of 9
(page number not for citation purposes)
Investigation schedule and follow-up
All patients with histologically proven pancreatic cancer
undergo appropriate diagnostic studies. The radiological
studies induced a chest X-ray, contrast enhanced com-
puted tomography (CT) or magnetic resonance imaging
(MRI). Laboratory tests included complete blood count,
electrolytes, blood urea nitrogen, creatinine, liver func-
tion tests, bilirubin, transaminases, alkaline phosphatase,
GT, total serum protein, albumine and CA 19-9. Further-
more, to meet the inclusion criteria an electrocardiogram
and a transesophageal echocardiogram is conducted by
cardiologists. HER2/neu overexpression and standardized
grading will be performed for each patient. Only in the
case of a grade 2 overexpression additional FISH analysis
will be done to assess a possible gene amplification.
Patients in whom the HER2 immunohistochemistry of
the tumor tissue was graded as grade 3 HER2/neu overex-
pression were included in the study, without performing
additional FISH analysis. Also patients with the grade 2
and proven HER2 gene amplification by FISH analysis
Table 2: Detailed overview of the treatment protocol
Cycle 0 12345 6 7




Trastuzumab i.v. X1 XXXXXXXXXXXXXX X X X X X X
Capecitabine p.o. 1–14 22–35 43–58 64–77 85–98 106–119 127–140
vital signs, physical exam2 XXXXXXXXXXXXXXXX X X X X X X
analgesic consumption3 XXXXXXXXXXXXXXXX X X X X X X
pain assessment3 XXXXXXXXXXXXXXXX X X X X X X
quality of life4 XX XX
diagnostic/remission5 XX XX
CA 19-9 level6 X X *XXXX X X
hematology7 X X# X§ X§ X X§ X§ X X§ X§ X X§ X§ X X§ X§ X X§ X§ X X§ X§
blood chemistry8 X XXXXX X X
toxicity (NCI CTC 3.0)9 X XXXX X X
ECG X X
TEE X X
1. Trastuzumab: initial dose 4 mg/kg body weight, subsequent cycles 2 mg/kg body weight
2. vitals signs and physical exam: height, weight, Karnofsky performance status, pulse rate, blood pressure, temperature
3. analgesic consumption and pain symptoms (visual analogue scale)
4. EORTC QLQ-C30 (v3.0) questionnaire
5. tumor diagnostic: imaging study, HER2/neu analysis; status of remission for at least 12 weeks: CT- or MRI Abdomen, CXR (CT-chest)
6. CA19-9: serum level (ELSIA), * no measurement if between time point 0 and 1st day of cycle 1 < 4 weeks
7. Hematology: complete blood count (CBC), differential blood count; # no measurement if between time point 0 and 1st day of cycle 1 < 1 weeks; 
§only CBC
8. Blood chemistry: total bilirubin, ALT, AST, alk. Phos., -GT, total protein, albumin, creatinine, uric acid, sodium, potassium, calcium
9. NCI: CTC vers. 3.0. If toxicity > 2 reevaluation by study physicalBMC Surgery 2009, 9:1 http://www.biomedcentral.com/1471-2482/9/1
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will be included in the study. To ensure a high quality of
histological analysis all samples were analyzed by a highly
specialized expert in pancreatic pathology (G. Klöppel,
M.D.; Department of Pathology, University of Kiel, Ger-
many). Furthermore, a thorough physical exam and meas-
urement of vital signs will be performed prior to the start
of the study as well as on day 1, 8 and 15 of each cycle.
Similarly, blood tests will be performed every week and
blood chemistry (including CA19-9 levels) on the begin-
ning of each new cycle (for details see Table 2). Further-
more, since both substances have potential cardiotoxic
side effects a transthoracic echocardiography is performed
ever 12 weeks.
Toxicity will be evaluated using the NCI CTC (v 3.0) prior
to the start of the study as well as at the beginning of each
new cycle. Quality of life will be assessed using the EORTC
QLQ-C30 questionnaire (v 3.0) prior to the start of the
study and at the beginning of the third cycle. The assess-
ment will then be repeated every other cycle. EORTC
QLQ-C30 serves as a general measure of quality of life in
cancer patients. It incorporates nine multi-item scales: five
functional scales (physical, role, cognitive, emotional,
and social); three symptom scales (fatigue, pain, and nau-
sea and vomiting); and a global health and quality-of-life
scale [18]. Specific symptoms (dyspnoea, insomnia, ano-
rexia, constipation, diarrhoea, and financial impact) are
measured as six single items. This instrument has been
used extensively with a variety of cancer patients and was
able to discriminate between individuals with metastatic
and non-metastatic disease, as well as between patients at
different stages of illness. The scale has good internal con-
sistency (alpha > 0.70), and good test re-test reliability
(0.80 to 0.90) [19].
In addition, analgesic consumption and assessment of
pain will be documented at the beginning of each week
using a visual analogue scale (VAS) for pain ranging from
1 to 10 with 10 as the highest pain score. Staging of the
tumor via chest X-ray, contrast enhanced computed tom-
ography or a magnetresonance imaging will be performed
on day 43, followed by restaging every other cycle.
Patients who are no longer treated with the study medica-
tions due to tumor progression or toxicity will be followed
for at least 12 months (max. 4 years).
Statistical considerations
Primary endpoint of this study is progression free survival
after 12 weeks. Secondary endpoints are listed in the sec-
tion "study design and objectives". The sample size calcu-
lation is based on the two-step minimax design by Simon
[20]. Trials evaluating Gemcitabine as monotherapy in
advanced pancreatic cancer show a median progression
free survival of 3 months, varying only little between dif-
ferent studies [21]. The combination of Trastuzumab and
Capecitabine would be considered ineffective if the
median progression-free survival after 3 months would be
50% or less. The combination therapy would, on the
other hand, be deemed effective if the progression-free
Table 3: Dose modification protocol according to the level of adverse reaction caused by capecitabine therapy (Toxicity according to 
NCI CTC Version 3.0)
Toxicity occurrence suggested measure dose during following cycle (% of original dose)
1 continue with current dose 100%
2 1st occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 100%
2nd occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 75%
3rd occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 50%
4th occurrence final discontinuation of treatment -
3 1st occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 75%
2nd occurrence discontinue treatment till restitution to grade 0 or 1 toxicity 50%
3rd occurrence final discontinuation of treatment -
4 1st occurrence final discontinuation of treatment or discontinuation till 
restitution to grade 0 or 1 toxicity
50%BMC Surgery 2009, 9:1 http://www.biomedcentral.com/1471-2482/9/1
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survival would be 70% or more. Assuming an accrual
period of 36 months and a follow-up period of 12 to 48
months, testing for a difference in hazard on level  = 0.05
with a power of 80% a study sample size of 37 patients is
needed. After 23 patients an interim analysis will be car-
ried out.
According to the "intention-to-treat" principle all patients
fulfilling the inclusion- and exclusion criteria and who
have started chemotherapy are included in the evaluation,
i.e. even patients who show a fast tumor progression, who
die before tumor progression can be evaluated or who die
due to treatment related toxicities are included. In addi-
tion, "per protocol" analysis of the primary end point will
be performed. For this purpose only patients who have
received at least 2 cycles of the combination therapy are
included. Furthermore, all patients who have received at
least one cycle of the combination therapy are evaluated
for toxicities and side-effects.
If less than 13 of the 23 patients during the interim anal-
ysis show progression-free survival the combination ther-
apy might be considered ineffective and the study could
be stopped. The degree of HER2 expression of the
included patients will be taken into account before the
trial is stopped. If, on the other hand, 13 or more of the
23 patients during interim analysis exhibit progression-
free survival the recruitment will be extended to 37
patients.
The progression free survival after 3 months will be calcu-
lated with a confidence interval of 95%. Progression free
survival and overall survival will be summarized by Kap-
lan and Meier estimate. The probability of remission
(complete or partial) over time will be calculated using
cumulative incidence rates. The duration of remission will
be summarized by Kaplan and Meier estimates. The clini-
cal benefit response (CBR) probability 12 weeks after ini-
tiation of therapy will be estimated by the number of
patients that exhibit a CBR within 12 weeks. The correla-
tion between the CA19-9 and HER2 levels with progres-
sion free survival time will be analyzed using Cox's
regression model. The rate of adverse events or severe
adverse events will be given using a 95% confidence inter-
val.
Discussion
Most patients with pancreatic cancer will have to be
treated by chemotherapy. So far only limited success has
been achieved with this kind of treatment. Addition of
multimodal therapies, including radiation and chemo-
therapy regimes has had only minimal effect on the prog-
nosis of these patients [22,23]. Up to now the standard
treatment for these patients is chemotherapy with gemcit-
abine which has been shown to be marginally more effec-
tive than 5-FU in alleviation of disease-related symptoms
[3]. Nevertheless the overall prognosis of these patients is
dismal [2]. Therefore, new treatment strategies including
new targeted therapies are necessary to improve the over-
all prognosis for patients with pancreatic cancer.
The anti-HER2 antibody trastuzumab is a promising new
candidate in the treatment of advanced pancreatic adeno-
carcinoma, because HER2 is overexpressed in a subset of
ductal adenocarcinoms of the pancreas [16]. Furthermore,
Trastuzumab has already shown its therapeutic potential
in combination with other chemotherapeutic drugs in the
treatment of HER2 overexpressing breast cancer [12]. In
addition a number of preclinical studies and pilot studies
in humans have shown the effectiveness of Trastuzumab
in HER2 overexpressing pancreatic adenocarcinoma [13-
15]. Because trastuzumab is generally well tolerated and
side effects are rare this compound is an ideal new candi-
date for the treatment of pancreatic cancer and there is a
clear interest in evaluating the clinical efficacy of this new,
highly specific compounds [24,25].
This study is a prospective, non-randomized multi-cen-
tered Phase II clinical trial evaluating the clinical effects of
Capecitabine in combination with the monoclonal anti-
HER2 antibody Trastuzumab in patients with non-resect-
able, HER2 overexpressing pancreatic cancer. Apart from
the oncological efficacy of this treatment combination, its
toxicity as well as the quality of life of this therapeutic reg-
imen will be assessed. Furthermore, the trial should pro-
vide evidence for the relationship between progression
free survival and CA19-9 plasma levels as a predictive
therapeutic factor. The results of this study will definitely
contribute to our current clinical and scientific knowledge
on the treatment of locally advanced pancreatic adenocar-
cinoma.
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